文献速递乳腺癌放疗姑息放疗与转移瘤

寡转移性乳腺癌根治性放疗的前瞻性II期试验结果

Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
PubMed 文献 · Radiother Oncol · 2017-09-21

这项前瞻性II期多中心试验评估了对所有转移灶行根治性放疗能否改善寡转移性乳腺癌患者的无进展生存期(PFS)。共纳入54例患者(92个转移灶),2年PFS为53%,2年局部控制率和总生存率分别为97%和95%,未记录到≥3级毒性。

要点

  • 根治性放疗至所有转移灶后2年PFS达53%,2年局部控制率97%。
  • 放疗耐受良好,未记录到≥3级毒性,仅2例出现2级疼痛和乏力。
  • 在等待随机试验数据前,对寡转移性乳腺癌可考虑根治性放疗并个体化推荐。

核心结论

  • 对寡转移性乳腺癌患者所有转移灶行根治性放疗可能获得长期无进展生存,且无显著治疗相关毒性。

研究设计与样本

  • 前瞻性II期多中心试验,纳入寡转移性乳腺癌(≤5个转移灶)、FDG-PET/CT分期、无脑转移、原发肿瘤控制的患者。
  • SBRT方案为30-45Gy分3次,IMRT总剂量60Gy分25次。
  • 假设根治性放疗可将2年PFS从文献报道的30%提高至50%。

主要发现

  • 中位随访30个月(范围6-55个月),1年和2年PFS分别为75%和53%。
  • 2年局部控制率和总生存率分别为97%和95%。
  • 转移部位:骨60个病灶、淋巴结23个、肺4个、肝5个。
  • 放疗耐受良好,未记录到≥3级毒性;2例出现2级疼痛和乏力。

临床怎么用

  • 在等待随机试验数据前,对寡转移性乳腺癌患者可考虑对所有转移灶行根治性放疗,推荐应个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We conducted a prospective phase II multicentric trial to determine if radical radiation therapy to all metastatic sites might improve the progression-free survival (PFS) in oligometastatic breast cancer patients. Secondary endpoints were local control (LC), overall survival (OS) and toxicity. METHODS AND MATERIALS: Inclusion criteria were the following: oligometastatic breast cancer with ≤5 metastatic sites, FDG-PET/CT staging, no brain metastases, primary tumor controlled. Radiotherapy could be delivered using stereotactic body radiotherapy (SBRT) technique or fractionated intensity modulated radiotherapy (IMRT). SBRT consisted of 30-45Gy in 3 fractions, while IMRT was delivered to a total dose of 60Gy in 25 fractions. We hypothesized that radical radiation therapy could increase the PFS from 30% (according to the published literature) to 50% at two years. RESULTS: 54 Patients with 92 metastatic lesions were enrolled. Forty-four were treated with SBRT, and 10 with IMRT. Forty-eight (89%) patients received a form of systemic therapy concomitantly to radiation therapy. Sites of metastatic disease were the following: bones 60 lesions, lymph nodes 23 lesions, lung 4 lesions, liver 5 lesions. After a median follow-up of 30months (range, 6-55months), 1- and 2-year PFS was 75% and 53%, respectively. Two-year LC and OS were 97% and 95%, respectively. Radiation therapy was well tolerated, and no Grade ≥3 toxicity was documented. Grade 2 toxicity were pain and fatigue in 2 cases. CONCLUSIONS: Patients with oligometastatic breast cancer treated with radical radiotherapy to all metastatic sites may achieve long-term progression-free survival, without significant treatment-related toxicity. While waiting for data from randomized trials, the use of radical radiation therapy to all metastatic sites in patients with oligometastatic breast cancer should be considered a valuable option, and its recommendation should be individualized.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Trovo M, Furlan C, Polesel J, et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol. 2017. PMID: 28943046. doi:10.1016/j.radonc.2017.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。